Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenbu Zhibi is a Traditional Chinese Medicine (TCM) herbal formula developed as a granule for the treatment of ankylosing spondylitis (AS). Developed by The Affiliated Jiangnan Hospital of Zhejiang Chinese Medical University, the formula is based on TCM principles of warming the kidney, tonifying essence, and dispelling wind-dampness to treat "Bi syndrome" (joint obstruction). It is primarily evaluated for its ability to reduce disease activity, improve spinal mobility, and alleviate pain in patients with AS. As a multi-component herbal preparation, it likely acts through various anti-inflammatory and immunomodulatory pathways, offering a potential alternative or adjunct to conventional therapies such as NSAIDs or TNF inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenbu Zhibi.